Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$1.17 +2.6%	$1.24	$0.64 ▼ $2.92	$46.42M	-0.73	42,070 shs	28,627 shs
JSPR Jasper Therapeutics	$2.84 -2.1%	$3.68	$2.27 ▼ $26.05	$47.13M	2.7	229,754 shs	99,762 shs
KLRS Kalaris Therapeutics	$3.56 +15.6%	$2.59	$2.14 ▼ $24.15	$57.60M	0.49	66,773 shs	328,105 shs
LGVN Longeveron	$0.83 +1.0%	$1.26	$0.63 ▼ $2.48	$12.47M	0.23	1.99 million shs	545,423 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	-0.85%	-1.27%	-23.53%	+10.38%	-8.24%
JSPR Jasper Therapeutics	-2.07%	-3.73%	-3.73%	-48.83%	-85.76%
KLRS Kalaris Therapeutics	+15.58%	+44.72%	+32.34%	+21.92%	+355,999,900.00%
LGVN Longeveron	+1.02%	+3.74%	-46.80%	-33.07%	-60.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRNS Barinthus Biotherapeutics	3.2023 of 5 stars	3.5	3.0	3.8	0.8	1.3
JSPR Jasper Therapeutics	2.9524 of 5 stars	4.3	4.0	1.1	1.7	0.0
KLRS Kalaris Therapeutics	0.5223 of 5 stars	1.0	0.0	2.6	3.3	0.0
LGVN Longeveron	3.4955 of 5 stars	3.5	5.0	2.2	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	3.00	Buy	$3.00	156.41% Upside
JSPR Jasper Therapeutics	2.60	Moderate Buy	$28.75	912.32% Upside
KLRS Kalaris Therapeutics	2.00	Hold	$3.00	-15.73% Downside
LGVN Longeveron	3.00	Buy	$7.67	823.81% Upside

Current Analyst Ratings Breakdown

Latest LGVN, BRNS, JSPR, and KLRS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/15/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$29.00 ➝ $25.00
8/15/2025	LGVN Longeveron	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$10.00 ➝ $3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral	$3.00
7/23/2025	KLRS Kalaris Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$3.00
7/8/2025	JSPR Jasper Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Sector Perform	$5.00
7/8/2025	JSPR Jasper Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$70.00 ➝ $12.00
7/8/2025	JSPR Jasper Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$50.00 ➝ $20.00
7/8/2025	JSPR Jasper Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
7/7/2025	JSPR Jasper Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $20.00
7/7/2025	JSPR Jasper Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	$14.97M	3.18	N/A	N/A	$2.52 per share	0.46
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$1.45 per share	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	$2.84 per share	N/A
LGVN Longeveron	$2.39M	5.27	N/A	N/A	$0.83 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.73	N/A	N/A	N/A	N/A	-54.70%	-44.75%	11/5/2025 (Estimated)
JSPR Jasper Therapeutics	-$71.27M	-$6.01	N/A	N/A	N/A	N/A	-172.28%	-128.34%	11/6/2025 (Estimated)
KLRS Kalaris Therapeutics	-$58.77M	N/A	0.00	∞	N/A	N/A	-81.02%	-65.15%	N/A
LGVN Longeveron	-$15.97M	-$6.28	N/A	N/A	N/A	-894.40%	-95.91%	-79.69%	11/11/2025 (Estimated)

Latest LGVN, BRNS, JSPR, and KLRS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	JSPR Jasper Therapeutics	-$1.20	-$1.74	-$0.54	-$1.74	N/A	N/A
8/13/2025	Q2 2025	KLRS Kalaris Therapeutics	-$0.51	-$0.61	-$0.10	-$0.61	N/A	N/A
8/13/2025	Q2 2025	LGVN Longeveron	-$0.35	-$0.33	+$0.02	-$0.33	$0.41 million	$0.32 million
8/7/2025	Q2 2025	BRNS Barinthus Biotherapeutics	-$0.29	-$0.52	-$0.23	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
KLRS Kalaris Therapeutics	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	7.89	7.89
JSPR Jasper Therapeutics	N/A	2.10	2.10
KLRS Kalaris Therapeutics	N/A	11.98	11.98
LGVN Longeveron	N/A	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
JSPR Jasper Therapeutics	79.85%
KLRS Kalaris Therapeutics	66.05%
LGVN Longeveron	10.01%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	10.70%
JSPR Jasper Therapeutics	4.60%
KLRS Kalaris Therapeutics	74.99%
LGVN Longeveron	11.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.72 million	36.36 million	N/A
JSPR Jasper Therapeutics	20	16.25 million	15.51 million	Optionable
KLRS Kalaris Therapeutics	110	18.70 million	4.68 million	N/A
LGVN Longeveron	20	15.18 million	13.48 million	Not Optionable

LGVN, BRNS, JSPR, and KLRS Headlines

Recent News About These Companies

Longeveron® to Present at the H.C. Wainwright 27th Annual Global Investment Conference

August 20, 2025 | globenewswire.com

Research Analysts Issue Forecasts for Longeveron Q3 Earnings

August 19, 2025 | americanbankingnews.com

Roth Capital Cuts Longeveron (NASDAQ:LGVN) Price Target to $3.00

August 18, 2025 | americanbankingnews.com

Longeveron Inc. Faces Regulatory and Manufacturing Challenges Threatening Financial Stability

August 16, 2025 | msn.com

Longeveron price target lowered to $3 from $10 at Roth Capital

August 16, 2025 | msn.com

Longeveron Posts 32% Revenue Drop in Q2

August 14, 2025 | aol.comA

Longeveron Inc. Reports Q2 2025 Financial Results

August 14, 2025 | msn.com

Longeveron® Announces Second Quarter 2025 Financial Results and Provides Business Update

August 14, 2025 | finance.yahoo.com

LGVN Focuses on Commercialization and Expanding Pipeline

August 14, 2025 | msn.com

Longeveron Inc. (LGVN) Q2 2025 Earnings Call Transcript

August 13, 2025 | seekingalpha.com

LongeveronÂ® Announces Second Quarter 2025 Financial Results and Provides Business Update

August 13, 2025 | globenewswire.com

Longeveron Inc (LGVN) Q2 2025: Everything You Need To Know Ahead Of Earnings

August 12, 2025 | finance.yahoo.com

Longeveron Inc. Closes Public Offering of Class A Common Stock and Short-Term Warrants Raising Approximately $5 Million

August 11, 2025 | quiverquant.comQ

Longeveron Announces Closing Of Up To $17.5 Million Public Offering

August 11, 2025 | globenewswire.com

Longeveron Announces Up To $17.5 Million Public Offering

August 8, 2025 | globenewswire.com

Longeveron Inc. to Announce Q2 2025 Financial Results and Business Update on August 13, 2025

August 5, 2025 | quiverquant.comQ

Longeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025

August 5, 2025 | globenewswire.com

Longeveron® Announces Licensing of New Cardiac Selective Induced Pluripotent Stem Cell Technology for Cardiovascular Disease

July 21, 2025 | globenewswire.com

Longeveron receives FDA approval for pediatric heart therapy IND

July 10, 2025 | uk.investing.com

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric ... - Seeking Alpha

July 10, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN, BRNS, JSPR, and KLRS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$1.17 +0.03 (+2.62%)

Closing price 08/28/2025 03:58 PM Eastern

Extended Trading

$1.19 +0.02 (+2.05%)

As of 08/28/2025 06:07 PM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Jasper Therapeutics NASDAQ:JSPR

$2.84 -0.06 (-2.07%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$2.90 +0.06 (+2.11%)

As of 05:36 AM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

Kalaris Therapeutics NASDAQ:KLRS

$3.56 +0.48 (+15.58%)

As of 08/28/2025 04:00 PM Eastern

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.

Longeveron NASDAQ:LGVN

$0.83 +0.01 (+1.02%)

Closing price 08/28/2025 04:00 PM Eastern

Extended Trading

$0.84 +0.01 (+0.61%)

As of 05:34 AM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time